Age - Related Macular Degeneration (AMD)
Conditions
Keywords
Sulcus, AMD, Age-related Macular Degeneration, IOL, Intra-Ocular Lens, Pseudophakic, Samsara Vision, Add-on, SINGIMT, lens-exchange
Brief summary
This study aims to expand the CE mark IFU of the SING IMT™ to pseudophakic (patients with an intraocular lents) patients with late stage of AMD (Age-Related Macular Degeneration) and bilateral central vision impairment. This randomized, international, multicenter study will evaluate the safety and efficacy of the device in this patient group. Findings will support regulatory submissions, clinical decision-making, and potential label expansion.
Detailed description
Eligible AMD patients with existing IOL on both eyes will be randomized to either have the SING-IMT device placed on top of the existing IOL, or to replace the existing IOL.
Interventions
PROCEDURELens-Exchange
The existing IOL will be removed and replaced by implanting SING IMT™ device in the sulcus
PROCEDUREAdd-on
The SING IMT™ device will be placed in front of the existing IOL and implanted in the sulcus.
Sponsors
VisionCare, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Be 55 years of age or older; 2. Subjects with late-stage AMD; Have retinal findings of geographic atrophy or disciform scar with foveal involvement in both eyes; 3. Had cataract surgery (with IOL implantation in both eyes) at least 6 months prior to enrollment; 4. BCDVA no better than 20/80 and no worse than 20/800 in both eyes. 5. Have adequate peripheral vision in the eye not scheduled for surgery, assessed by observation of ambulation. 6. Achieve using the ETS, at least 2-lines (10 or more letters) improvement in distance on the ETDRS chart in the eye scheduled for surgery. 7. Have an Anterior chambre depth (ACD) of at least 2.5 mm, measured from endothelium, in both eyes. 8. Have an ECD of at least 1600 cells per square mm in both eyes. 9. Be willing to participate in a postoperative training program for the use of the SING IMT™ implant. 10. Review and sign the IEC approved Informed Consent Form (ICF) prior to any clinical investigation-related procedures being performed. 11. Patient is registered with the national social security or equivalent in the country where consent is signed 12. A woman is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: 13, Not a woman of childbearing potential (WOCBP): A WOCBP who agrees to follow contraceptive guidance starting with the screening visit and through to the end of the study
Exclusion criteria
A. Bilateral Ocular Conditions (affecting both eyes): 1. Evidence of active choroidal neovascularization (CNV), or treatment for CNV within the past six (6) months. 2. Diabetic retinopathy. 3. Retinal vascular diseases. 4. History of retinal detachment. 5. Retinitis pigmentosa. 6. Intraocular tumor. 7. Corneal Stromal or Endothelial Dystrophies (for example corneal guttata)Corneal guttata. 8. Patient predisposing to eye rubbing B. Surgical Eye Conditions: 9. Narrow angle (i.e., \< Schaffer grade 2). 10. Axial length \<21 mm or \>26 mm. 11. Any history or current ocular or intraocular inflammation, infection, or edema, including but not limited to: - Uveitis, iritis, keratitis, keratouveitis, microbial keratoconjunctivitis. 12. Plate haptic shape IOL implanted. 13. Vitrectomized eye. 14. Zonular weakness, instability, presence of pseudoexfoliation. 15. Iris abnormalities, including but not limited to: Transillumination defects (e.g., pigment dispersion syndrome), aniridia, iris neovascularization. 16. Any IOL already implanted in the sulcus. 17. Presence of toric or multifocal IOL types. 18. Optic Nerve Disease C. Systemic or Other General Conditions: 19. A history of steroid-induced IOP elevation uncontrolled, glaucoma, or preoperative IOP \>22 mmHg. 20. Known sensitivity to post-operative medications. 21. Significant communication impairment or severe neurological disorders. 22. Administration of any investigational product within 30 days prior to enrolment or planned participation in another clinical investigation during this study. 23. Any condition or situation that, in the opinion of the investigator, may: * Put the subject at significant risk, * Confound the clinical investigation results, or * Interfere significantly with the subject's participation in the study. 24. Individuals under legal care (e.g., incarcerated patients or those under legal guardianship) who are unable to understand and provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| percentage of ECD loss | at baseline, then at 1, 3 and 6 months | assessed within each treatment group relative to baseline (pre-surgery). The ECD loss should not exceed 23% |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incision size required for device implantation | baseline | measurement of the incision size |
| Number of Surgical Complications, AEs and SAEs | at baseline, then at 1, 3 and 6 months | Assess number of safety events comparing to similar procedures. |
| Acuity | at baseline, then at 1, 3 and 6 months | Change in near and distance best corrected acuity in implanted eyes |
| Patient-reported outcomes | at baseline, then at 1, 3 and 6 months | Using the Impact of Vision Impairment (IVI) questionnaire, 28 questions are answered, providing 4 different scores: 1. Vision-related quality of life Average of all items (ranging from 0 to 2.9) 2. Reading and accessing information Average of (Q1, Q3, Q5, Q6, Q7, Q8, Q9, Q14, Q15), (ranging from 0 to 2.7) 3. Mobility and Independence Average of (Q2, Q4, Q10, Q11, Q12, Q13, Q16, Q17, Q18, Q19, Q20), (ranging from 0 to 3) 4. Emotional well-being Average of (Q21, Q22, Q23, Q24, Q25, Q26, Q27, Q28), (ranging from 0 to 3) |
Countries
France, Germany, Italy
Contacts
CONTACTFaustino Vidal Aroca
CONTACTWaza Hadjebi
Outcome results
None listed